Navigation Links
Pancreatic Islets in Forefront of Diabetes Research
Date:4/14/2009

Cells could play major role in treatment, if supply is adequate, study finds

TUESDAY, April 14 (HealthDay News) -- Pancreatic islets, which are hormone-producing cells, are becoming more prominent in diabetes research and could play a major role in future treatments, according to U.S. experts.

"The primary objective of islet-based research is to cure diabetes," John S. Kaddis, of the City of Hope National Medical Center, in Duarte, Calif., and his colleagues wrote in the April 15 issue of the Journal of the American Medical Association, a themed issue on diabetes.

"Perhaps the most prominent clinical application of this research is currently in the form of cell replacement therapy," they noted. "With the exception of one report in a type 2 diabetes cohort, islet transplantation has been used exclusively for a subset of individuals with type 1 diabetes mellitus and was shown, at least temporarily, to improve glucose control and, in a few cases, to lead to insulin independence."

Cell replacement therapy involves the transplantation of pancreatic islets from a donated pancreas to a person with diabetes. The goal is to restore the function of beta cells in the pancreas. The destruction of these cells causes type 1 diabetes.

"Although islet transplantation has been shown to offer both protection against long-term complications of the disease and significant improvement in quality of life, several obstacles remain, such as limited engraftment [acceptance of the islets within the recipient], chronic immunosuppression and inconsistent supply of human islets," the researchers noted. "These issues must be addressed if the procedure is to be used as a standard of care for qualified individuals."

To meet the increasing demand for human islets for transplantation and research, islet-sharing networks have been established. Between September 2001 and August 2008, 297.6 million islets were produced by 14 laboratories in the Islet Cell Resource (ICR) consortium, with 67 percent of the islets used for basic science research and 31 percent for clinical purposes, according in background information in a news release from the journal.

"The importance of human pancreatic islets, clinically or for basic science research, is substantiated by the number and quality of studies being performed that rely on these preparations," the authors wrote. "Data available through the ICR as of August 2008 indicate that a total of 151 national and international scientists received human islets for use in both intramural research performed by the consortium as well as 182 clinical and basic science projects submitted to the consortium for support."

"Human pancreatic islets will be critical for restoration of beta-cell function in patients with diabetes," they concluded. "Even given adequate funding levels, the ongoing challenges to supplying human islets must be addressed for the successful exploration of therapeutic options for this chronic and debilitating disease."

More information

The American Diabetes Association has more about islet transplantation.



-- Robert Preidt



SOURCE: Journal of the American Medical Association, news release, April 14, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. New technique invented to reveal pancreatic stem cells
2. Fox Chase performs the world’s first successful ViKY robot-assisted surgery for pancreatic tumors
3. Obesity Tied to Poor Pancreatic Cancer Surgery Outcomes
4. NCCN Announces Updates to Pancreatic Adenocarcinoma Guidelines
5. Study Links Blood Type and Pancreatic Cancer
6. Personalized genome sequencing reveals coding error in gene for inherited pancreatic cancer
7. Alcohol consumption may increase pancreatic cancer risk
8. Georgetown researcher: 2 or more drinks a day may increase pancreatic cancer risk
9. U-M Researchers ID Gene Involved in Pancreatic Cancer
10. Optical techniques show continued promise in detecting pancreatic cancer
11. Determining risk for pancreatic cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Pancreatic Islets in Forefront of Diabetes Research
(Date:6/25/2017)... ... June 25, 2017 , ... CareSet Labs released the Root NPI ... This is a new, greatly improved version of the Doctor Referral teaming dataset commonly ... Fred Trotter and subsequently called the the “Doctor Referral Dataset” as released by Medicare ...
(Date:6/24/2017)... ... June 24, 2017 , ... Genes Advice, a new company ... Florida and Texas doctors' offices and clinics. This breakthrough testing is part of ... recognizes the role genes play in determining an individual's tolerance of and reaction ...
(Date:6/24/2017)... ... , ... The weather is heating up and the days are getting longer, ... aware that the summer months provide more than warmer temperatures that are perfect for ... negatively affected from direct exposure to the sun. When it comes to the security ...
(Date:6/23/2017)... ... June 23, 2017 , ... "The Better Care Reconciliation Act ... harm to people with all chronic conditions, including mental illnesses, while increasing the ... the Affordable Care Act (ACA) requirement that insurers cover pre-existing conditions, it does ...
(Date:6/23/2017)... ... 24, 2017 , ... Studies show evidence that carotenoids and antioxidants derived either ... in these patients. , But how often do ophthalmologists and optometrists in Sweden recommend ... risk of or with early symptoms of AMD? A study published recently ...
Breaking Medicine News(10 mins):
(Date:6/9/2017)... Calif. , June 9, 2017 AirXpanders, ... company focused on the design, manufacture, sale and distribution ... market on the progress of its commercial roll-out in ... now available in more than one hundred (100) medical ... AeroForm offers a needle-free alternative for women ...
(Date:6/7/2017)... , June 7, 2017 Endo International plc ... 7, 2017, the Hon. Joseph R. Goodwin , ... West Virginia , entered a case ... Pelvic Repair System Products Liability Litigation (the "MDL") that ... cases to provide expert disclosures on specific causation within ...
(Date:6/3/2017)... 3, 2017  Eli Lilly and Company (NYSE: ... from the Phase 3 MONARCH 2 study showed ... inhibitor, in combination with fulvestrant, significantly improved progression-free ... in women with hormone-receptor-positive (HR+), human epidermal growth ... have relapsed or progressed after endocrine therapy (median ...
Breaking Medicine Technology: